Drug Profile
APG C 20
Alternative Names: APG-C-20Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Avergen Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioblastoma; Malignant melanoma
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Glioblastoma in Germany
- 28 Aug 2020 No recent reports of development identified for research development in Malignant-melanoma in Germany
- 14 Jul 2016 Early research in Glioblastoma in Germany (unspecified route)